US20050049226A1 - Preparation of (S)-clopidogrel and related compounds - Google Patents
Preparation of (S)-clopidogrel and related compounds Download PDFInfo
- Publication number
- US20050049226A1 US20050049226A1 US10/963,707 US96370704A US2005049226A1 US 20050049226 A1 US20050049226 A1 US 20050049226A1 US 96370704 A US96370704 A US 96370704A US 2005049226 A1 US2005049226 A1 US 2005049226A1
- Authority
- US
- United States
- Prior art keywords
- acid
- group
- enantiomerically enriched
- chlorophenyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title abstract description 15
- 150000001875 compounds Chemical class 0.000 title description 13
- 238000002360 preparation method Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 71
- 230000008569 process Effects 0.000 claims abstract description 56
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000003054 catalyst Substances 0.000 claims abstract description 35
- -1 (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester Chemical class 0.000 claims abstract description 20
- MRDUURPIPLIGQX-UHFFFAOYSA-N 2-(2-chlorophenyl)acetonitrile Chemical compound ClC1=CC=CC=C1CC#N MRDUURPIPLIGQX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 12
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims abstract description 12
- 150000002466 imines Chemical class 0.000 claims abstract description 11
- DCASRSISIKYPDD-AWEZNQCLSA-N (2s)-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-ium-5-yl)acetate Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)O)=CC=CC=C1Cl DCASRSISIKYPDD-AWEZNQCLSA-N 0.000 claims abstract description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 125000004185 ester group Chemical group 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 29
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 125000003368 amide group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000004793 Polystyrene Substances 0.000 claims description 9
- 239000011324 bead Substances 0.000 claims description 9
- 229920002223 polystyrene Polymers 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 125000003944 tolyl group Chemical group 0.000 claims description 8
- 125000005023 xylyl group Chemical group 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 7
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 6
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 6
- VYGSFTVYZHNGBU-UHFFFAOYSA-N trichloromethanesulfonic acid Chemical compound OS(=O)(=O)C(Cl)(Cl)Cl VYGSFTVYZHNGBU-UHFFFAOYSA-N 0.000 claims description 6
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 4
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical class ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 claims description 4
- HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical class NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- 229910004373 HOAc Inorganic materials 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 3
- 239000003377 acid catalyst Substances 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 2
- 0 [1*]C.[2*]C.[H][C@](C(C)=O)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 Chemical compound [1*]C.[2*]C.[H][C@](C(C)=O)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 10
- 150000003840 hydrochlorides Chemical class 0.000 description 7
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 6
- 229960003009 clopidogrel Drugs 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- JXMUSLFGOYRHHE-CQSZACIVSA-N (2s)-2-(2-chlorophenyl)-2-(2-thiophen-2-ylethylamino)acetonitrile Chemical class ClC1=CC=CC=C1[C@@H](C#N)NCCC1=CC=CS1 JXMUSLFGOYRHHE-CQSZACIVSA-N 0.000 description 3
- VHZAAODXMCAZFO-XNTDXEJSSA-N [H]/C(=N\CCC1=CC=CS1)C1=C(Cl)C=CC=C1 Chemical compound [H]/C(=N\CCC1=CC=CS1)C1=C(Cl)C=CC=C1 VHZAAODXMCAZFO-XNTDXEJSSA-N 0.000 description 3
- CIKXOIWXKYSYGZ-INIZCTEOSA-N [H][C@](C(C)=O)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 Chemical compound [H][C@](C(C)=O)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 CIKXOIWXKYSYGZ-INIZCTEOSA-N 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 2
- JFDVAYOTONCKQN-AWEZNQCLSA-N [H][C@](C#N)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 Chemical compound [H][C@](C#N)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 JFDVAYOTONCKQN-AWEZNQCLSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VQCAKDCFTBIDOF-UHFFFAOYSA-N thieno[3,2-b]pyridine-2-carbonitrile Chemical compound C1=CC=C2SC(C#N)=CC2=N1 VQCAKDCFTBIDOF-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- APPSEYCZIRBRKU-LLVKDONJSA-N C[C@H](c(cccc1)c1Cl)NCCc1ccc[s]1 Chemical compound C[C@H](c(cccc1)c1Cl)NCCc1ccc[s]1 APPSEYCZIRBRKU-LLVKDONJSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GBDGUVVODFTDNJ-XZPBZCASSA-M N#C[C@H](C1=CC=CC=C1Cl)N1CCC2=C(C=CS2)C1.[Cl-].[H][C@@](C#N)(C1=C(Cl)C=CC=C1)N([H])([H])CCC1=CC=CS1 Chemical compound N#C[C@H](C1=CC=CC=C1Cl)N1CCC2=C(C=CS2)C1.[Cl-].[H][C@@](C#N)(C1=C(Cl)C=CC=C1)N([H])([H])CCC1=CC=CS1 GBDGUVVODFTDNJ-XZPBZCASSA-M 0.000 description 1
- OXHJSDVHZNUBEN-OVWKBUNZSA-N NCCC1=CC=CS1.[H]/C(=N\CCC1=CC=CS1)C1=C(Cl)C=CC=C1.[H]C(=O)C1=C(Cl)C=CC=C1 Chemical compound NCCC1=CC=CS1.[H]/C(=N\CCC1=CC=CS1)C1=C(Cl)C=CC=C1.[H]C(=O)C1=C(Cl)C=CC=C1 OXHJSDVHZNUBEN-OVWKBUNZSA-N 0.000 description 1
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- JXMUSLFGOYRHHE-CQSZACIVSA-O [H][C@@](C#N)(C1=C(Cl)C=CC=C1)[N+]([H])([H])CCC1=CC=CS1 Chemical compound [H][C@@](C#N)(C1=C(Cl)C=CC=C1)[N+]([H])([H])CCC1=CC=CS1 JXMUSLFGOYRHHE-CQSZACIVSA-O 0.000 description 1
- GKTWGGQPFAXNFI-OAHLLOKOSA-N [H][C@](C(=O)OC)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 Chemical compound [H][C@](C(=O)OC)(C1=C(Cl)C=CC=C1)N1CCC2=C(C=CS2)C1 GKTWGGQPFAXNFI-OAHLLOKOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Definitions
- the present invention relates to a process for enantioselective preparation of (S)-Clopidogrel, a potent platelet aggregation inhibitor, and related compounds. More particularly, the present invention relates to a process for the preparation of (S)-Clopidogrel in high enantioselectivity and yield.
- (S)-Clopidogrel is used as an antithrombotic agent for treatment of patients with vascular diseases, myocardial infraction and stroke.
- the present invention employs a novel approach, which does not require enzymatic or classical resolution techniques to obtain a final product having high enantioselectivity (ee).
- the present invention overcomes the disadvantages of the prior art described above by providing a process, which enables one to obtain an enantiomerically pure or enantiomerically enriched product without the need for laborious procedures and separations.
- the present invention provides a process for preparing an enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula: which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)- ⁇ -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester represented by the formula: the process including the step of:
- the present invention further provides a process for producing enantiomerically enriched derivative of (S)alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula: the process including the steps of:
- the present invention still further provides a process for preparing an enantiomerically enriched (S)- ⁇ , ⁇ -(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile represented by the formula: which is an intermediate in the preparation of enantiomerically enriched (S)- ⁇ -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5-(4H)-acetic acid methyl ester represented by the formula: the process including the step of:
- the present invention also provides process for producing enantiomerically enriched (S)alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula:
- the process includes the steps of:
- the present invention provides a process for the preparation of (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester (Clopidogrel) and related compounds.
- the process involves the condensation of 2-chlorobenaldehyde with 2-(2-amioethyl) thiophene to yield the corresponding imine. Reaction of the resulting imine with HCN in the presence of a catalyst yields the corresponding cyano amine with enantiomeric excess (hereinafter ee) in the range of 75 to 85% ee.
- the present invention does not rely on biocatalysts or classical resolution methods to produce high in the final product. This is achieved by using a catalyst represented by the formula:
- This catalyst can be prepared by a procedure described in a publication by Petr Vachel and Eric N. Jacobsen, Org. Letters , Vol. 2, No. 6, p.867-870 (2000). This catalyst is sometimes referred to as “Jacobsen non-metallic asymmetric Strecker catalyst.”
- the resulting amine or its salt i.e., the HCl salt
- 1,3 dioxolane may be treated with 1,3 dioxolane to yield the corresponding cyano pyrido thiophene.
- the Clopidogrel may be isolated by treatment of the cyano pyrido thiophene with acid and an alcohol, such as, methanol.
- the present invention provides a process for preparing an enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula: which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)- ⁇ -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester.
- the ester is represented by the following formula:
- the process includes the step of contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula: and an HCN source.
- the contacting step is optionally carried out in the presence of a catalyst represented by the formula:
- R 1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R 2 is a substituent at the 4 or 5 position of the thiophene ring; each R 1 and R 2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl; and R 3 is a hydrocarbyl group; and R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; the contacting being at a temperature and length of time sufficient to
- R 3 is a linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms or any combination thereof.
- Compounds wherein R 3 is methyl, ethyl or a mixture thereof are preferred.
- the derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process including the step of contacting an R 1 substituted derivative of 2-chlorobenzaldehyde and an R 2 substituted derivative of 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, such as, an acid, molecular sieves or a combination thereof, at a temperature and length of time sufficient to produce the derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
- a catalyst such as, an acid, molecular sieves or a combination thereof
- the process further includes the step of contacting the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethyl-amino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of the acid.
- the contacting step is carried out at a temperature and length of time sufficient to produce a salt of the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, which is represented by the formula:
- the acid HX can be a mineral acid, an organic acid or a mixture thereof.
- examples of such acids include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof.
- HCl and HOAc are preferred.
- the salt of the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile can be purified by recrystallization from a suitable recrystallizing solvent, such as, hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone or a mixture thereof.
- a suitable recrystallizing solvent such as, hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone or a mixture thereof.
- the recrystallizing solvent is a mixture including toluene and isopropanol in a 2:1 ratio by weight.
- the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent are then contacted, optionally in the presence of an acid catalyst, such as, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof.
- an acid catalyst such as, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof.
- the contacting is carried out at a temperature and length of time sufficient to produce enantiomerically enriched ⁇ -5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, which is represented by the formula:
- the formaldehyde equivalent in the context of the present invention can be formaldehyde, paraformaldehyde, 1,3 dioxolane, formaline, hexamethylenetetraamine or a mixture thereof.
- a solution of HCN is prepared by adding trimethylsilyl cyanide (TMSCN) (0.59 g, 0.004 mmol) and methanol (0.140 g, 0.004 mmol) to a solution of toluene (5 mL) at 0° C. and stirring for 1 h.
- TMSCN trimethylsilyl cyanide
- methanol 0.140 g, 0.004 mmol
- Imine 3 is added neat to a reaction vessel and catalyst 4a (5 mol %) is added to the reaction vessel.
- the vessel is cooled to ⁇ 15° C. and the HCN solution mentioned above is added.
- the reaction is allowed to stir for 15 h.
- HCl salt 6 is added to a solution of 1,3-dioxane and heated for 3 h at 90° C. for 8 h. The reaction mixture is allowed to cool and then water (20 mL) is added. The resulting solution is extracted with ethyl acetate (3 ⁇ 20 mL). The organics are dried over sodium sulfate, filtered and evaporated to yield clear oil. The title compound is isolated in near quantitative yield (chemical purity 94%).
- Compound 7 can be transformed to the title compound by any method known in the art for the conversion of a nitrile into the corresponding methyl ester.
- the process is carried out by condensing 2-chlorobenzaldehyde and 2-aminoethylthipheneto to give the corresponding imine 3.
- Imine 3 is then treated with a chiral catalyst and HCN at ⁇ 15° C., i.e., under the asymmetric Strecker conditions.
- the chiral catalyst can be either one of the Jacobsen non-metallic Strecker catalyst 1 c or 1b, which are described in Petr Vachel and Eric N. Jacobsen, Org. Letters , Vol. 2, No. 6, p.867-870 (2000).
- the Jacobsen non-metallic Strecker catalyst 1 c is referred to herein as catalyst 4a.
- the Jacobsen non-metallic Strecker catalyst 1b is referred to herein as catalyst 4b.
- the difference between 4a and 4b is that 4a is soluble in organic solvents, while 4b is bound to polystyrene beads. If 4a is used as a catalyst, an 85% ee of the Strecker adduct is obtained. When 4b is used as a catalyst, an ee of 75% is obtained. If the process is practiced in the absence of the Jacobsen non-metallic Strecker catalysts, a further resolution step would be required.
- the temperature range for this reaction can be as low as ⁇ 78° C. and as high as 25° C.
- the temperature at which the reaction is carried out affects the enantiomeric excess obtained in the final product, with the higher temperatures leading to lower selectivities.
- the resulting Strecker adduct 5 is converted to the corresponding HCl salt 6.
- the salt of Strecker adduct 5 may be formed by treatment with any inorganic acid, i.e., HBr, hydrogen sulfate, and taurochlorate.
- HCl salt 6 may be enantiomerically upgraded by recrystallization from a 2:1 toluene: Isopropyl alcohol solution or be carried onto the next step.
- the HCl salt 6 is converted to cyano thiophene 7. This is accomplished by any of the well-known methods for Pictet-Spengler type reactions (for leading references see: Ohno et al, Chem. Pharm. Bull., 1994, 42, 1676-1678).
- Compound 5 or 6 can be treated with acid and formaldehyde or formaldehyde equivalent to give the compound 7.
- Compound 7 can then be converted to Clopidogrel by treatment with methanol in the presence of any suitable acid known in the art.
- compound 7 can be hydrolyzed to the corresponding carboxylic acid by reagents known for this transformation and then treated with any reagent known to convert carboxylic acids to methyl ester.
- (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester known as (S)-Clopidogrel, has utility as a platelet aggregation inhibitor and is described as being an antithrombotic agent in patients with vascular diseases, myocardial infraction and stroke.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
A process for producing enantiomerically enriched (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula:
Is provided, wherein R1 and R2 are hydrogens and R3 is methyl (i.e., (S)-Clopidogrel). The process includes the steps of: (a) contacting N-2-chlorobenz-aldehyde-ylidene-1-ethylamine-2 (2-thiophenyl)imine and an HCN source, in the presence of a non-metallic asymmetric Strecker catalyst to form enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile; (b) contacting the enantiomerically enriched (s)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile and a formaldehyde equivalent, in the presence of an acid catalyst to form enantiomerically enriched α-5 (4,5,6,7-tetrahydro[3,2-c] thienopyridyl) (2-chlorobenzyl)-nitrile; and (c) contacting the enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c] thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group to form enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid.
Is provided, wherein R1 and R2 are hydrogens and R3 is methyl (i.e., (S)-Clopidogrel). The process includes the steps of: (a) contacting N-2-chlorobenz-aldehyde-ylidene-1-ethylamine-2 (2-thiophenyl)imine and an HCN source, in the presence of a non-metallic asymmetric Strecker catalyst to form enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile; (b) contacting the enantiomerically enriched (s)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile and a formaldehyde equivalent, in the presence of an acid catalyst to form enantiomerically enriched α-5 (4,5,6,7-tetrahydro[3,2-c] thienopyridyl) (2-chlorobenzyl)-nitrile; and (c) contacting the enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c] thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group to form enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid.
Description
- 1. Field of the Invention
- The present invention relates to a process for enantioselective preparation of (S)-Clopidogrel, a potent platelet aggregation inhibitor, and related compounds. More particularly, the present invention relates to a process for the preparation of (S)-Clopidogrel in high enantioselectivity and yield. (S)-Clopidogrel is used as an antithrombotic agent for treatment of patients with vascular diseases, myocardial infraction and stroke.
- 2. Description of the Prior Art
- Currently there are two known processes for the preparation of (S)-Clopidogrel. Each of these processes relies on classical resolution or enzymatic techniques to introduce the sole chiral center into the molecule.
- U.S. Pat. No. 4,847,265 describes a method of preparation of Clopidogrel employing classical resolution techniques.
- French Patent Applications Nos. 2,530,247 and 2,769,313 describe commercial methods that are currently used to synthesize Clopidogrel.
- When classical resolution techniques are employed, the following problems must be overcome: (1) a suitable resolving agent must be found; (2) the resolving reagent must be recycled to make the resolution economical; and (3) isolation and racemization of the starting material from the mother liquor must be carried out efficiently to improve the economics and overall yield.
- The problems with enzymatic resolution techniques are similar to classical resolution techniques in that low yield of the desired enantiomer makes it necessary to isolate and racemize starting material from the mother liquor. An added problem with enzymatic resolution is low volumetric throughput and tedious work up procedures.
- To overcome these disadvantages of the prior art, laborious procedures and separations would be required to either enrich the racemic product in one or the other enantiomer or to efficiently and completely separate one enantiomer from the other.
- The present invention employs a novel approach, which does not require enzymatic or classical resolution techniques to obtain a final product having high enantioselectivity (ee).
- In addition, the present invention overcomes the disadvantages of the prior art described above by providing a process, which enables one to obtain an enantiomerically pure or enantiomerically enriched product without the need for laborious procedures and separations.
- The present invention provides a process for preparing an enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula:
which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester represented by the formula:
the process including the step of: -
- contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula:
and an HCN source, optionally in the presence of a catalyst represented by the formula: - wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring;
- wherein each R1 and R2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
- wherein R3 is a hydrocarbyl group; and
- wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; the contacting being at a temperature and length of time sufficient to form the enantiomerically enriched derivative of (S)-alpha-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile.
- contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula:
-
-
- (a) contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl)imine represented by the formula:
and an HCN source, optionally in the presence of a catalyst represented by the formula:
wherein the contacting is carried out at a temperature and length of time sufficient to form a derivative of enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, represented by the formula: - (b) contacting the derivative of enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile and a formaldehyde equivalent, optionally in the presence of a catalyst, wherein the contacting is carried out at a temperature and length of time sufficient to form a derivative of enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, represented by the formula:
- (c) contacting the derivative of enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form a derivative of an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
- wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; wherein each R1 and R2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
- wherein R3 is a hydrocarbyl group; and
- wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof.
- (a) contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl)imine represented by the formula:
- The present invention still further provides a process for preparing an enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile represented by the formula:
which is an intermediate in the preparation of enantiomerically enriched (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5-(4H)-acetic acid methyl ester represented by the formula:
the process including the step of: -
- contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine represented by the formula:
and an HCN source in the presence of a catalyst represented by the formula: - wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads and a mixture thereof, the contacting being at a temperature and length of time sufficient to form the enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile.
- contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine represented by the formula:
-
- The process includes the steps of:
-
- (a) contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl)imine represented by the formula:
and an HCN source, optionally in the presence of a catalyst represented by the formula: - wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof, wherein the contacting is carried out at a temperature and length of time sufficient to form an enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, represented by the formula:
- (b) contacting the enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile and a formaldehyde equivalent, optionally in the presence of a catalyst, wherein the contacting is carried out at a temperature and length of time sufficient to form enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, represented by the formula:
- (c) contacting the enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
wherein R3 is a hydrocarbyl group.
- (a) contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl)imine represented by the formula:
- The advantages of the current process include the production of (S)-Clopidogrel in high ee, high yield and with good volumetric throughput without the need to resort to enzymatic or classical resolution techniques.
- The present invention provides a process for the preparation of (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester (Clopidogrel) and related compounds.
- The process involves the condensation of 2-chlorobenaldehyde with 2-(2-amioethyl) thiophene to yield the corresponding imine. Reaction of the resulting imine with HCN in the presence of a catalyst yields the corresponding cyano amine with enantiomeric excess (hereinafter ee) in the range of 75 to 85% ee.
-
- This catalyst can be prepared by a procedure described in a publication by Petr Vachel and Eric N. Jacobsen, Org. Letters, Vol. 2, No. 6, p.867-870 (2000). This catalyst is sometimes referred to as “Jacobsen non-metallic asymmetric Strecker catalyst.”
- The resulting amine or its salt, i.e., the HCl salt, may be treated with 1,3 dioxolane to yield the corresponding cyano pyrido thiophene. Then, the Clopidogrel may be isolated by treatment of the cyano pyrido thiophene with acid and an alcohol, such as, methanol.
- The present invention provides a process for preparing an enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula:
which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester. -
-
- In the compounds described above, R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; each R1 and R2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl; and R3 is a hydrocarbyl group; and R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; the contacting being at a temperature and length of time sufficient to form the enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile.
- Preferably, R3 is a linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms or any combination thereof. Compounds wherein R3 is methyl, ethyl or a mixture thereof are preferred.
- The derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process including the step of contacting an R1 substituted derivative of 2-chlorobenzaldehyde and an R2 substituted derivative of 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, such as, an acid, molecular sieves or a combination thereof, at a temperature and length of time sufficient to produce the derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
- The process further includes the step of contacting the enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethyl-amino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of the acid. The contacting step is carried out at a temperature and length of time sufficient to produce a salt of the enantiomerically enriched derivative of (S)-α,α-(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, which is represented by the formula:
- The acid HX can be a mineral acid, an organic acid or a mixture thereof. Examples of such acids include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof. HCl and HOAc are preferred.
- The salt of the enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile can be purified by recrystallization from a suitable recrystallizing solvent, such as, hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone or a mixture thereof.
- Preferably, the recrystallizing solvent is a mixture including toluene and isopropanol in a 2:1 ratio by weight.
- The enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent, are then contacted, optionally in the presence of an acid catalyst, such as, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof. The contacting is carried out at a temperature and length of time sufficient to produce enantiomerically enriched α-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, which is represented by the formula:
-
- wherein R1 and R2 are as previously described herein above.
- The formaldehyde equivalent in the context of the present invention can be formaldehyde, paraformaldehyde, 1,3 dioxolane, formaline, hexamethylenetetraamine or a mixture thereof.
- When R1 and R2 are hydrogens, and R3 is methyl, the process of the present invention produces (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester, which is also known as (S)-Clopidogrel.
- The various aspects of the present invention are described in the following examples, which are only illustrative and therefore, should not be construed as limiting of the scope of the invention.
-
- To a solution of hexane (20 mL), at 0° C., was added 4 Å molecular sieves (1 g), 2-chlorobenaldehyde (0.55 g, 0.0048 mmol), and 2(2-aminoethyl) thiophene. The solution was allowed to stir for 1 h, filtered, and evaporated to yield the title compound. The title compound was used in the next step without further purification.
(S)-2-chloro-alpha-[(phenylsulfonyl)oxy]benzeneaceto nitrile(3): - A solution of HCN is prepared by adding trimethylsilyl cyanide (TMSCN) (0.59 g, 0.004 mmol) and methanol (0.140 g, 0.004 mmol) to a solution of toluene (5 mL) at 0° C. and stirring for 1 h. Imine 3 is added neat to a reaction vessel and catalyst 4a (5 mol %) is added to the reaction vessel. The vessel is cooled to −15° C. and the HCN solution mentioned above is added. The reaction is allowed to stir for 15 h.
- The completion of the reaction is determined by monitoring the reaction with TLC (10% ethyl acetate in hexane). Amine 5 can be isolated as on oil in near quantitative yield (95% chemical purity) and in 85% ee by evaporation of the reaction solvent, or it may be converted to the corresponding HCl salt 6 by treatment with 1 M HCl in acetic acid (2 equiv). The oil is not purified. Recrystallization of HCl salt 6 may be accomplished by heating in a solution of toluene: isopropyl alcohol (2:1 ratio).
Alpha-5 (4,5,6,7-tetrahydro (3,2-c) thienopyridyl)(2-chlorobenzyl)-nitrile (7): - HCl salt 6 is added to a solution of 1,3-dioxane and heated for 3 h at 90° C. for 8 h. The reaction mixture is allowed to cool and then water (20 mL) is added. The resulting solution is extracted with ethyl acetate (3×20 mL). The organics are dried over sodium sulfate, filtered and evaporated to yield clear oil. The title compound is isolated in near quantitative yield (chemical purity 94%).
- (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester (Clopidogrel):
- Compound 7 can be transformed to the title compound by any method known in the art for the conversion of a nitrile into the corresponding methyl ester.
- The process is carried out by condensing 2-chlorobenzaldehyde and 2-aminoethylthipheneto to give the corresponding imine 3. Imine 3 is then treated with a chiral catalyst and HCN at −15° C., i.e., under the asymmetric Strecker conditions.
- The chiral catalyst can be either one of the Jacobsen non-metallic Strecker catalyst 1 c or 1b, which are described in Petr Vachel and Eric N. Jacobsen, Org. Letters, Vol. 2, No. 6, p.867-870 (2000). The Jacobsen non-metallic Strecker catalyst 1 c is referred to herein as catalyst 4a. The Jacobsen non-metallic Strecker catalyst 1b is referred to herein as catalyst 4b. The difference between 4a and 4b is that 4a is soluble in organic solvents, while 4b is bound to polystyrene beads. If 4a is used as a catalyst, an 85% ee of the Strecker adduct is obtained. When 4b is used as a catalyst, an ee of 75% is obtained. If the process is practiced in the absence of the Jacobsen non-metallic Strecker catalysts, a further resolution step would be required.
- The temperature range for this reaction can be as low as −78° C. and as high as 25° C. The temperature at which the reaction is carried out affects the enantiomeric excess obtained in the final product, with the higher temperatures leading to lower selectivities.
- When the asymmetric Strecker reaction is complete, the resulting Strecker adduct 5 is converted to the corresponding HCl salt 6. The salt of Strecker adduct 5 may be formed by treatment with any inorganic acid, i.e., HBr, hydrogen sulfate, and taurochlorate. HCl salt 6 may be enantiomerically upgraded by recrystallization from a 2:1 toluene: Isopropyl alcohol solution or be carried onto the next step. The HCl salt 6 is converted to cyano thiophene 7. This is accomplished by any of the well-known methods for Pictet-Spengler type reactions (for leading references see: Ohno et al, Chem. Pharm. Bull., 1994, 42, 1676-1678).
- Compound 5 or 6 can be treated with acid and formaldehyde or formaldehyde equivalent to give the compound 7. Compound 7 can then be converted to Clopidogrel by treatment with methanol in the presence of any suitable acid known in the art. Similarly, compound 7 can be hydrolyzed to the corresponding carboxylic acid by reagents known for this transformation and then treated with any reagent known to convert carboxylic acids to methyl ester.
- (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester, known as (S)-Clopidogrel, has utility as a platelet aggregation inhibitor and is described as being an antithrombotic agent in patients with vascular diseases, myocardial infraction and stroke.
- The present invention has been described with particular reference to the preferred embodiments. It should be understood that variations and modifications thereof can be devised by those skilled in the art without departing from the spirit and scope of the present invention. Accordingly, the present invention embraces all such alternatives, modifications and variations that fall within the scope of the appended claims.
Claims (34)
1. A process comprising the step of:
contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula:
and an HCN source, optionally in the presence of a catalyst represented by the formula:
wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; wherein each R1 and R2 is independently selected from the group consisting of: H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
wherein R3 is a hydrocarbyl group; and
wherein R is selected from the group consisting of: phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; said contacting being at a temperature and length of time sufficient to form said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile.
2. The process of claim 1 , wherein said derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process comprising the step of contacting an R1 substituted derivative of 2-chlorobenzaldehyde and an R2 substituted derivative of 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce said derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
3. The process of claim 2 , wherein said catalyst is selected from the group consisting of: an acid, molecular sieves, and a combination thereof.
4. The process of claim 1 , further comprising the step of contacting said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethyl-amino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of said acid, at a temperature and length of time sufficient to produce a salt of said enantiomerically enriched derivative of (S)-α,α-(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, said salt being represented by the formula:
5. The process of claim 4 , wherein said acid HX is selected from the group consisting of: mineral acid, organic acid, and a mixture thereof.
6. The process of claim 4 , wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
7. The process of claim 4 , wherein said acid is selected from the group consisting of: HCl, HOAc, and a mixture thereof.
8. The process of claim 4 , further comprising the step of:
recrystallizing said salt of said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile from a recrystallizing solvent.
9. The process of claim 8 , wherein said solvent is selected from the group consisting of: hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone and a mixture thereof.
10. The process of claim 8 , wherein said recrystallizing solvent is a mixture comprising toluene and isopropanol in a 2:1 ratio by weight.
11. The process of claim 4 , further comprising the step of:
contacting said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce enantiomerically enriched α-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile represented by the formula:
12. The process of claim 11 , wherein said formaldehyde equivalent is selected from the group consisting of: formaldehyde, paraformaldehyde, formaline, hexamethylenetetraamine, 1,3 dioxolane and a mixture thereof.
13. The process of claim 11 , wherein said catalyst is an acid.
14. The process of claim 13 , wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
15. The process of claim 11 , wherein said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile salt is the hydrochloride salt thereof.
16. The process of claim 1 , wherein R3 is selected from the group consisting of: a linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms and any combination thereof.
17. The process of claim 11 , further comprising:
contacting said derivative of enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form a derivative of an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; wherein each R1 and R2 is independently selected from the group consisting of: H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
wherein R3 is a hydrocarbyl group; and
wherein R is selected from the group consisting of: phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof.
18-20. (canceled)
21. A process comprising the step of:
contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine represented by the formula:
and an HCN source in the presence of a catalyst represented by the formula:
wherein R is selected from the group consisting of: phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads and a mixture thereof, said contacting being at a temperature and length of time sufficient to form said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile.
22. The process of claim 21 , wherein said N-2-chlorobenz-aldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process comprising the step of contacting 2-chlorobenzaldehyde and 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce said N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
23. The process of claim 22 , wherein said catalyst is selected from the group consisting of: an acid, molecular sieves, and a combination thereof.
24. The process of claim 21 , further comprising the step of:
contacting said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of said acid, at a temperature and length of time sufficient to produce a salt of said enantiomerically enriched (S)-α,α-(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, said salt being represented by the formula:
25. The process of claim 24 , wherein said acid HX is selected from the group consisting of: mineral acid, organic acid, and a mixture thereof.
26. The process of claim 24 , wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
27. The process of claim 24 , wherein said acid is selected from the group consisting of: HCl, HOAc, and a mixture thereof.
28. The process of claim 24 , further comprising the step of:
recrystallizing said salt of enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile from a recrystallizing solvent.
29. The process of claim 28 , wherein said solvent is selected from the group consisting of: hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone and a mixture thereof.
30. The process of claim 28 , wherein said recrystallizing solvent is a mixture comprising toluene and isopropanol in a 2:1 ratio by weight.
31. The process of claim 24 , further comprising the step of:
contacting said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce enantiomerically enriched α-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile represented by the formula:
32. The process of claim 31 , wherein said formaldehyde equivalent is selected from the group consisting of: formaldehyde, paraformaldehyde, formaline, hexamethylenetetraamine, 1,3 dioxolane and a mixture thereof.
33. The process of claim 31 , wherein said catalyst is an acid.
34. The process of claim 33 , wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
35. The process of claim 31 , further comprising:
contacting said enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
wherein R3 is a hydrocarbyl group.
36-38. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/963,707 US20050049226A1 (en) | 2003-04-23 | 2004-10-13 | Preparation of (S)-clopidogrel and related compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/421,564 US6858734B2 (en) | 2003-04-23 | 2003-04-23 | Preparation of (S)-Clopidogrel and related compounds |
US10/963,707 US20050049226A1 (en) | 2003-04-23 | 2004-10-13 | Preparation of (S)-clopidogrel and related compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/421,564 Division US6858734B2 (en) | 2003-04-23 | 2003-04-23 | Preparation of (S)-Clopidogrel and related compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050049226A1 true US20050049226A1 (en) | 2005-03-03 |
Family
ID=33298706
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/421,564 Expired - Fee Related US6858734B2 (en) | 2003-04-23 | 2003-04-23 | Preparation of (S)-Clopidogrel and related compounds |
US10/963,707 Abandoned US20050049226A1 (en) | 2003-04-23 | 2004-10-13 | Preparation of (S)-clopidogrel and related compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/421,564 Expired - Fee Related US6858734B2 (en) | 2003-04-23 | 2003-04-23 | Preparation of (S)-Clopidogrel and related compounds |
Country Status (3)
Country | Link |
---|---|
US (2) | US6858734B2 (en) |
TW (1) | TW200503688A (en) |
WO (1) | WO2004094374A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008134600A1 (en) | 2007-04-27 | 2008-11-06 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US8835407B2 (en) | 2009-05-13 | 2014-09-16 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100681512B1 (en) | 2005-03-08 | 2007-02-09 | 주식회사 한서켐 | Novel Intermediates for Clopidogrel Production and Clopidogrel Manufacturing Method Using the Same |
JP2008540546A (en) * | 2005-05-10 | 2008-11-20 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate clopidogrel formulation |
JP2008543843A (en) * | 2005-06-13 | 2008-12-04 | エラン ファーマ インターナショナル リミテッド | Combination preparation of nanoparticulate clopidogrel and aspirin |
CN100463909C (en) * | 2005-09-08 | 2009-02-25 | 浙江华海药业股份有限公司 | A kind of synthetic method of thienotetrahydropyridine acetonitrile compound |
DE102006028451A1 (en) * | 2006-06-21 | 2008-01-10 | Studiengesellschaft Kohle Mbh | Process for the preparation of N-acyl-α-aminonitriles |
US20090247569A1 (en) * | 2006-08-03 | 2009-10-01 | Claude Singer | Process for Preparing Clopidogrel Bisulphate |
KR100990949B1 (en) | 2008-06-09 | 2010-10-29 | 엔자이텍 주식회사 | Method for preparing clopidogrel and its derivatives |
CN102241690B (en) | 2010-05-13 | 2015-08-12 | 天津药物研究院 | Thienopyridine ester derivative, the Preparation Method And The Use of one class nitrile group-containing |
CN102432626B (en) * | 2011-11-14 | 2014-07-02 | 连云港宏业化工有限公司 | Synthesis method of 4,5,6,7-tetrahydrothiophene[3,2-c] pyridine hydrochloride |
CN104379589A (en) * | 2012-05-07 | 2015-02-25 | 塞利克斯比奥私人有限公司 | Prodrugs of anti-platelet agents |
WO2023012479A1 (en) | 2021-08-03 | 2023-02-09 | Liqmeds Worldwide Limited | An oral pharmaceutical solution of clopidogrel |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2530247B1 (en) | 1982-07-13 | 1986-05-16 | Sanofi Sa | NOVEL THIENO (3, 2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATION |
FR2623810B2 (en) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2622191B1 (en) * | 1987-10-22 | 1991-06-21 | Sanofi Sa | PROCESS FOR THE PREPARATION OF N- (2-CHLORO-BENZYL) -2 ETHYLAMINE AND INTERMEDIATE PRODUCTS IN THIS PREPARATION |
HU225503B1 (en) * | 1997-05-13 | 2007-01-29 | Sanofi Aventis | Novel 2-(2-halophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides and process for producing them |
FR2769313B1 (en) | 1997-10-06 | 2000-04-21 | Sanofi Sa | DERIVATIVES OF HYDROXYACETIC ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES |
-
2003
- 2003-04-23 US US10/421,564 patent/US6858734B2/en not_active Expired - Fee Related
-
2004
- 2004-03-26 WO PCT/US2004/009496 patent/WO2004094374A2/en active Application Filing
- 2004-04-22 TW TW093111358A patent/TW200503688A/en unknown
- 2004-10-13 US US10/963,707 patent/US20050049226A1/en not_active Abandoned
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008134600A1 (en) | 2007-04-27 | 2008-11-06 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US20100292268A1 (en) * | 2007-04-27 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use |
US8343995B2 (en) | 2007-04-27 | 2013-01-01 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US8853236B2 (en) | 2007-04-27 | 2014-10-07 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US9125945B2 (en) | 2007-04-27 | 2015-09-08 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US9623045B2 (en) | 2007-04-27 | 2017-04-18 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US10034947B2 (en) | 2007-04-27 | 2018-07-31 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US10512697B2 (en) | 2007-04-27 | 2019-12-24 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
EP3766493A1 (en) | 2007-04-27 | 2021-01-20 | CyDex Pharmaceuticals, Inc. | Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin |
US8835407B2 (en) | 2009-05-13 | 2014-09-16 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
US9399067B2 (en) | 2009-05-13 | 2016-07-26 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
US10111863B2 (en) | 2009-05-13 | 2018-10-30 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
US6858734B2 (en) | 2005-02-22 |
WO2004094374A3 (en) | 2006-08-24 |
WO2004094374A2 (en) | 2004-11-04 |
TW200503688A (en) | 2005-02-01 |
US20040214878A1 (en) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100990949B1 (en) | Method for preparing clopidogrel and its derivatives | |
US6858734B2 (en) | Preparation of (S)-Clopidogrel and related compounds | |
CA2436323C (en) | Process for preparing clopidogrel | |
JP4903819B2 (en) | Hydroxyacetic acid ester derivatives, their production and use as synthetic intermediates | |
US6180793B1 (en) | Process for the preparation of a pharmacologically active substance | |
US20100160635A1 (en) | Industrial process for preparation of clopidogrel hydrogen sulphate | |
US6215005B1 (en) | Intermediates and process for the preparation thereof | |
EP1669359B1 (en) | A process for the preparation of olanzapine and an intermediate therefor | |
US20050049415A1 (en) | Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives | |
EP1501838B1 (en) | A process for the preparation of clopidogrel | |
US5821369A (en) | Racemisation process | |
US20120123124A1 (en) | Manufacturing process for Tadalafil from racemic or L-tryptophan | |
CA2218654C (en) | Synthesis of (s)-3-(2-thienylthio) butyric acid and analogs | |
WO2006086921A1 (en) | A process for the preparation of clopidogrel | |
EP2107061A1 (en) | Process for the preparation of optically enriched clopidogrel | |
US6639095B1 (en) | Process for preparing optically active α-hydroxy acids and derivatives thereof | |
US7060831B2 (en) | Process for the preparation of tetrahydrothieno[3,2-c] pyridine derivatives | |
KR100681512B1 (en) | Novel Intermediates for Clopidogrel Production and Clopidogrel Manufacturing Method Using the Same | |
WO2009080469A1 (en) | Process for the preparation of clopidogrel bisulphate form i | |
KR101088859B1 (en) | Method for preparing clopidogrel and its derivatives | |
EP1980563A1 (en) | Procedure for the preparation of methyl (+)-(S)-Alpha-(O-chlorophenyl)-6,7-dihydrothieno-[3,2-C]pyridine-5(4H) acetate | |
JP2001199980A (en) | Method for producing optically active homocysteine thiolactone salt | |
CN114249674A (en) | Clopidogrel intermediate compound | |
KR20080034611A (en) | Method for preparing clopidogrel hydrogen sulfate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |